These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 27699497)
1. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection. Saccà F; Pane C; De Rosa A; Matarazzo M; Brescia Morra V Neurol Sci; 2017 Mar; 38(3):501-502. PubMed ID: 27699497 [No Abstract] [Full Text] [Related]
2. Hepatitis C virus (HCV) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis. Tagawa A; Ogawa T; Tetsuka S; Otsuka M; Hashimoto R; Kato H; Ando K; Tanabe H Mult Scler Relat Disord; 2016 Sep; 9():155-7. PubMed ID: 27645365 [TBL] [Abstract][Full Text] [Related]
3. Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod. Calvi A; De Riz M; Lecchi E; Pietroboni A; Ghezzi L; Scarioni M; Carandini T; Pellegrinelli A; Maurichi A; Galimberti D; Scarpini E J Neurol Sci; 2017 Oct; 381():296-297. PubMed ID: 28991701 [No Abstract] [Full Text] [Related]
4. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis. Ward MD; Jones DE; Goldman MD Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342 [TBL] [Abstract][Full Text] [Related]
5. Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis. Walker S; Brew B J Clin Neurosci; 2016 Sep; 31():217-8. PubMed ID: 27168454 [TBL] [Abstract][Full Text] [Related]
6. Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases. Peaureaux D; Pignolet B; Biotti D; Bucciarelli F; Gaina J; Bucur C; Clanet M; Martin-Blondel G; Brassat D Mult Scler; 2015 Apr; 21(5):671-2. PubMed ID: 25305251 [No Abstract] [Full Text] [Related]
7. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis. Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666 [TBL] [Abstract][Full Text] [Related]
8. Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod. Hernández Clares R; Sánchez Pedreño P; García Vazquez E; Carreón Guarnizo E; Meca Lallana JE Neurologia (Engl Ed); 2018 Jun; 33(5):348-349. PubMed ID: 28535923 [No Abstract] [Full Text] [Related]
9. 6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis. Racca V; Rovaris M; Vaini E; Cavarretta R; Ferratini M; Toccafondi A; Di Rienzo M J Am Coll Cardiol; 2016 Nov; 68(18):2027-2029. PubMed ID: 27788858 [No Abstract] [Full Text] [Related]
10. [Switching therapy from natalizumab to fingolimod: reduction of the washout time?]. Sánchez-Gundín J; Flor García A; Martí Gil C; Gómez Romero L Farm Hosp; 2015 Sep; 39(5):314-5. PubMed ID: 26546944 [No Abstract] [Full Text] [Related]
11. Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis. Christopher KL; Elner VM; Demirci H Ophthalmic Plast Reconstr Surg; 2017; 33(3):e73-e75. PubMed ID: 27533512 [TBL] [Abstract][Full Text] [Related]
12. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. Hunter SF; Agius M; Miller DM; Cutter G; Barbato L; McCague K; Meng X; Agashivala N; Chin P; Hollander E J Neurol Sci; 2016 Jun; 365():190-8. PubMed ID: 27206905 [TBL] [Abstract][Full Text] [Related]
13. Disability progression in relapsing MS is more than just lesions: The lesson of fingolimod. Fox RJ Mult Scler; 2015 Jun; 21(7):843-4. PubMed ID: 25948627 [No Abstract] [Full Text] [Related]
14. Severe tumefactive rebound of multiple sclerosis following fingolimod cessation. Salam S; Mihalova T; Siripurapu R BMJ Case Rep; 2016 Jun; 2016():. PubMed ID: 27261513 [No Abstract] [Full Text] [Related]
15. Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis. Lingenberg A; Laidet M; Armand S; Herrmann FR; Assal F; Lalive PH; Allali G J Neurol Sci; 2017 Dec; 383():105-107. PubMed ID: 29246593 [No Abstract] [Full Text] [Related]
16. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients. Hovi A; Airas L J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874 [No Abstract] [Full Text] [Related]
17. Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis. Sharim J; Tashjian R; Golzy N; Pouratian N J Clin Neurosci; 2016 Aug; 30():166-168. PubMed ID: 26970935 [TBL] [Abstract][Full Text] [Related]
18. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility. Montgomery SM; Kusel J; Nicholas R; Adlard N J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362 [TBL] [Abstract][Full Text] [Related]
19. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients. De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768 [TBL] [Abstract][Full Text] [Related]
20. Catastrophic Magnetic Resonance Images in the Central Nervous System of Patients Undergoing Treatment with Fingolimod. Fragoso YD; Sato HK CNS Neurosci Ther; 2016 Jul; 22(7):633-5. PubMed ID: 27140433 [No Abstract] [Full Text] [Related] [Next] [New Search]